Molecular genetic pathways in Parkinson's disease: A review

Clinical Science

Volumn 109, Issue 4, 2005, Pages 355-364

  Jain, Shushant ^a,b,c   Wood, Nicholas W ^a   Healy, Daniel G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

synuclein; Dardarin; Genetic basis; Lewy body; Mendelian genetics; Parkin; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; NR4A2 PROTEIN; PARKIN; PINK1 PROTEIN; PROTEIN; SYNPHILIN 1 PROTEIN; UCHL 1 PROTEIN; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; LINKAGE ANALYSIS; MOLECULAR GENETICS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ALPHA-SYNUCLEIN; CHROMOSOME MAPPING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 26844555183     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050106     Document Type: Review

References (126)

1. Twelves, D., Perkins, K. S. and Counsell, C. (2003) Systematic review of incidence studies of Parkinson's disease. Mov. Disord. 18, 19-31
2. Parkinson, J. (1817) An essay on the shaking palsy, Sherwood, Neely and Jones, London
3. Brissaud, E. (1895) Nature et pathogenic de la maladie de Parkinson. In Leçons sur les Malades Nerveuses, pp. 488-501 Masson, Paris
4. Birkmayer, W. and Hornykiewicz, O. (1962) The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. Arch. Psychiatry Nervenkrankh. 203, 560-574
5. Langston, J. W., Ballard, P., Tetrud, J. W. and Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980
6. Wirdefeldt, K., Gatz, M., Pawitan, Y. and Pedersen, N. L. (2005) Risk and protective factors for Parkinson's disease. A study in Swedish twins. Ann. Neurol. 57, 27-33
7. Hardy, J., Cookson, M. R. and Singleton, A. (2003) Genes and parkinsonism. Lancet Neurol. 2, 221-228
8. Polymeropoulos, M. H., Lavedan, C., Leroy, E. et al. (1997) Mutation in α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
9. Kitada, T., Asakawa, S., Hattori, N. et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (London) 392, 605-608
10. Bonifati, V., Rizzu, P., van Baren, M. J. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259
11. Valente, E. M., Abou-Sleiman, P. M., Caputo, V. et al. (2004) Hereditary early onset Parkinson's disease is caused by mutations in PINK1. Science 304, 1158-1160
12. Paisán-Rui'z, C., Jain, S., Evans, E. W. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 18, 595-600
13. Zimprich, A., Biskup, S., Leitner, P. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 18, 601-607
14. Leroy, E., Boyer, R., Auburger, G. et al. (1988) The ubiquitin pathway in Parkinson's disease. Nature (London) 395, 451-452
15. Le, W. D., Xu, P., Jankovic, J. et al. (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33, 85-89
16. Marx, E P., Holzmann, C., Strauss, K. M. et al. (2003) Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 12, 1223-1231
17. Eriksen, J. L., Dawson, T. M., Dickson, D. W. and Petrucelli, L. (2003) Caught in the act: α-synuclein is the culprit in Parkinson's disease. Neuron 40, 453-456
18. Shen, J. and Cookson, M. R. (2004) Mitochondria and dopamine; new insights into recessive Parkinsonism. Neuron 43, 301-304
19. Paviour, D. C., Surtees, R. A. and Lees, A. J. (2004) Diagnostic considerations in juvenile parkinsonism. Mov. Disord. 19, 123-135
20. Healy, D. G., Abou-Sleiman, P. M. and Wood, N. W. (2004) PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. Lancet Neurol. 3, 652-662
21. Kruger, R., Kuhn, W., Muller, T. et al. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
22. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C. et al. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173
23. Spillantini, M., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R. and Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature (London) 388, 839-840
24. Singleton, A. B., Farrer, M., Johnson, J. et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841
25. Ibanez, P., Bonnet, A. M., Debarges, B. et al. (2004) Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171
26. Muenter, M. D., Forno, L. S., Hornykiewicz, O. et al. (1998) Hereditary form of parkinsonism-dementia. Ann. Neurol. 43, 768-781
27. Chartier-Harlin, M. C., Kachergus, J., Roumier, C. et al. (2004) α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169
28. Shimura, H., Hattori, N., Kubo, S. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305
29. Shimura, H., Schlossmacher, M. G., Hattori, N. et al. (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269
30. Cookson, M. R. (2003) Parkin's substrates and the pathways leading to neuronal damage. Neuromol. Med. 3, 1-13
31. Hedrich, K., Djarmati, A., Schafer, N. et al. (2004) DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62, 389-394
32. Farrer, M., Chan, P., Chen, R. et al. (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293-300
33. Hattori, N. and Mizuno, Y. (2004) Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364, 722-724
34. Khan, N. L., Scherfler, C., Graham, E. et al. (2005) Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64, 134-136
35. Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S. et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415-416
36. Nichols, W. C., Pankratz, N., Hernandez, D. et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365, 410-412
37. Di Fonzo, A., Rohé, C. F., Ferreira, J. et al. (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365, 412-415
38. Lohmann, E., Periquet, M., Bonifati, V. et al. (2003) How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 54, 176-185
39. Farrer, M., Chan, P., Chen, R. et al. (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293-300
40. van de Warrenburg, B. P., Lammens, M., Lucking, C. B. et al. (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555-557
41. Canet-Aviles, R. M., Wilson, M. A., Miller, D. W. et al. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U.S.A. 101, 9103-9108
42. Moore, D. J., Zhang, L., Troncoso, J. et al. (2005) Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14, 71-84
43. Abou-Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J. and Wood, N. W. (2003) The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54, 283-286
44. 18F-dopa PET study. Ann. Neurol. 52, 849-853
45. Hering, R., Strauss, K. M., Tao, X. et al. (2004) Novel homozygous PE64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum. Mutat. 24, 321-329
46. Valente, E. M., Salvi, S., Ialongo, T. et al. (2004) PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56, 336-341
47. Hatano, Y., Li, Y., Sato, K. et al. (2004) Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol. 56, 424-427
48. Rohe, C. F., Montagna, P., Breedveld, G. et al. (2004) Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann. Neurol. 56, 427-431
49. Rogaeva, E., Johnson, J., Lang, A. E. et al. (2004) Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. Neurol. 61, 1898-1904
50. Healy, D. G., Abou-Sleiman, P. M., Gibson, J. M. et al. (2004) PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63, 1486-1488
51. Rogaeva, E., Johnson, J., Lang, A. E. et al. (2004) Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. Neurol. 61, 1898-1904
52. Schapira, A. H., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B. and Marsden, C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet i, 1269
53. Dawson, T. M. and Dawson, V. L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 30, 819-822
54. Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L. and Di Monte, D. A. (2002) The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: paraquat and α-synuclein. J. Biol. Chem. 277, 1641-1644
55. Kowall, N. W., Hantraye, P., Brouillet, E., Beal, M. F., McKee, A. C. and Ferrante, R. J. (2000) MPTP induces α-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211-213
56. Abysalh, J. C., Kuchnicki, L. L. and Larochelle, D. A. (2003) The identification of pats1, a novel gene locus required for cytokinesis in Dictyostelium discoideum. Mol. Biol. Cell. 14, 14-25
57. 2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J. 16, 998-1008
58. Aharon-Peretz, J., Rosenbaum, H. and Gershoni-Baruch, R. (2004) Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. New Engl. J. Med. 351, 1972-1977
59. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M. E. and Sidransky, E. (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81, 70-73
60. Sato, C., Morgan, A., Lang, A. E. et al. (2005) Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov. Disord. 20, 367-370
61. Machaczka, M., Rucinska, M., Skotnicki, A. B. and Jurczak, W. (1999) Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am. J. Hematol. 61, 216-217
62. Bembi, B., Zambito Marsala, S., Sidransky, E. et al. (2003) Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61, 99-101
63. Clark, L. N., Nicolai, A., Afridi, S. et al. (2004) Pilot association study of the β-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov. Disord. 20, 100-103
64. Feany, M. B. (2004) New genetic insights into Parkinson's disease. New Engl. J. Med. 351, 1937-1940
65. Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. and Lansbury, P. T. (2002) The UCHL-1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218
66. Osaka, H., Wang, Y. L., Takada, K. et al. (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 12, 1945-1958
67. Nishikawa, K., Li, H., Kawamura, R. et al. (2003) Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 30, 176-183
68. Tanner, C. M., Ottman, R., Goldman, S. M. et al. (1999) Parkinson disease in twins: an etiologic study. JAMA, J. Am. Med. Assoc. 281, 341-346
69. Sveinbjornsdottir, S., Hicks, A. A., Jonsson, T. et al. (2000) Familial aggregation of Parkinson's disease in Iceland. New Engl. J. Med. 343, 1765-1770
70. Rocca, W. A., McDonnell, S. K., Strain, K. J. et al. (2004) Familial aggregation of Parkinson's disease: The Mayo Clinic family study. Ann. Neurol. 56, 495-502
71. Marder, K., Levy, G., Louis, E. D. et al. (2003) Familial aggregation of early- and late-onset Parkinson's disease. Ann. Neurol. 54, 507-513
72. Le Couteur, D. G., Muller, M., Yang, M. C., Mellick, G. D. and McLean, A. J. (2002) Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev. Environ. Health 17, 51-64
73. Gorell, J. M., Peterson, E. L., Rybicki, B. A. and Johnson, C. C. (2004) Multiple risk factors for Parkinson's disease. J. Neurol. Sci. 217, 169-174
74. Botstein, D. and Risch, N. (2003) Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat. Genet. 33 (Suppl.), 228-237
75. Cardon, L. R. and Palmer, L. J. (2003) Population stratification and spurious allelic association. Lancet 361, 598-604
76. Storey, J. D. and Tibshirani, R. (2003) Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U.S.A. 100, 9440-9445
77. Carlson, C. S., Eberle, M. A., Kruglyak, L. and Nickerson, D. A. (2004) Mapping complex disease loci in whole-genome association studies. Nature (London) 429, 446-452
78. Maniatis, N., Collins, A., Gibson, J., Zhang, W., Tapper, W. and Morton, N. E. (2004) Positional cloning by linkage disequilibrium. Am. J. Hum. Genet. 74, 846-855
79. Gasser, T., Muller-Myhsok, B., Wszolek, Z. K. et al. (1998) A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet. 18, 262-265
80. DeStefano, A. L., Lew, M. F., Golbe, L. I. et al. (2002) PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am. J. Hum. Genet. 70, 1089-1095
81. West, A. B., Zimprich, A., Lockhart, P. J. et al. (2001) Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur. J. Hum. Genet. 9, 659-666
82. Hicks, A. A., Petursson, H., Jonsson, T. et al. (2002) A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52, 549-555
83. Payami, H., Zareparsi, S., James, D. and Nutt, J. (2002) Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. Arch. Neurol. 59, 848-850
84. Li, Y. J., Scott, W. K., Hedges, D. J. et al. (2002) Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 70, 985-993
85. Pankratz, N., Nichols, W. C., Uniacke, S. K. et al. (2002) Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am. J. Hum. Genet. 71, 124-135
86. Scott, W. K., Nance, M. A., Watts, R. L. et al. (2001) Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA, J. Am. Med. Assoc. 286, 2239-2244
87. Martinez, M., Brice, A., Vaughan, J. R. et al. (2004) Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. J. Med. Genet. 41, 900-907
88. Tan, E. K., Khajavi, M., Thornby, J. I., Nagamitsu, S., Jankovic, J. and Ashizawa, T. (2000) Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55, 533-538
89. Altmuller, J., Palmer, L. J., Fischer, G., Scherb, H. and Wjst, M. (2001) Genomewide scans of complex human diseases: true linkage is hard to find. Am. J. Hum. Genet. 69, 936-950
90. Hutton, M., Lendon, C. L., Rizzu, P. et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (London) 393, 702-705
91. Hutton, M. (2000) Molecular genetics of chromosome 17 tauopathies. Ann. NY Acad. Sci. 920, 63-73
92. Conrad, C., Andreadis, A., Trojanowski, J. Q. et al. (1997) Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann. Neurol. 41, 277-281
93. Houlden, H., Baker, M., Morris, H. R. et al. (2001) Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56, 1702-1706
94. Wszolek, Z. K., Pfeiffer, R. F., Tsuboi, Y. et al. (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62, 1619-1622
95. van de Warrenburg, B. P., Lammens, M., Lucking, C. B. et al. (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555-557
96. Healy, D. G., Abou-Sleiman, P. M., Lees, A. J. et al. (2004) Tau gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Neurosurg. Psychiatry 75, 962-965
97. Kruger, R., Vieira-Saecker, A. M., Kuhn, W. et al. (1999) Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/apolipoprotein E genotype. Ann. Neurol. 45, 611-617
98. Farrer, M., Maraganore, D. M., Lockhart, P. et al. (2001) α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10, 1847-1851
99. Tan, E. K., Chai, A., Teo, Y. Y. et al. (2004) α-Synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 62, 128-131
100. Tan, E. K., Matsuura, T., Nagamitsu, S., Khajavi, M., Jankovic, J. and Ashizawa, T. (2000) Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology 54, 1195-1198
101. Mizuta, I., Nishimura, M., Mizuta, E., Yamasaki, S., Ohta, M. and Kuno, S. (2002) Meta-analysis of α-synuclein/NACP polymorphism in Parkinson's disease in Japan. J. Neurol. Neurosurg. Psychiatry 73, 350
102. Mellick, G. D., Maraganore, D. M. and Silburn, P. A. (2005) Australian data and meta-analysis lend support for α-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci. Lett. 375, 112-116
103. Khan, N., Graham, E., Dixon, P. et al. (2001) Parkinson's disease is not associated with the combined α-synuclein/apolipoprotein E susceptibility genotype. Ann. Neurol. 49, 665-668
104. Parsian, A., Racette, B., Zhang, Z. H. et al. (1998) Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson's disease. Neurology 51, 1757-1759
105. Spadafora, P., Annesi, G., Pasqua, A. A. et al. (2003) NACP-REP1 polymorphism is not involved in Parkinson's disease: a case-control study in a population sample from southern Italy. Neurosci. Lett. 351, 75-78
106. Tan, E. K., Tan, C., Shen, H. et al. (2003) α-Synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci. Lett. 336, 70-72
107. Izumi, Y., Morino, H., Oda, M. et al. (2001) Genetic studies in Parkinson's disease with an α-synuclein/NACP gene polymorphism in Japan. Neurosci. Lett. 300, 125-127
108. Chiba-Falek, O., Kowalak, J. A., Smulson, M. E. and Nussbaum, R. L. (2005) Regulation of α-synuclein expression by poly (ADP Ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am. J. Hum. Genet. 76, 478-479
109. Holzmann, C., Kruger, R., Saecker, A. M. et al. (2003) Polymorphisms of the α-synuclein promoter: expression analyses and association studies in Parkinson's disease. J. Neural Transm. 110, 67-76
110. Kirik, D., Rosenblad, C., Burger, C. et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791
111. Dev, K. K., Hofele, K., Barbieri, S., Buchman, V. L. and van der Putten, H. (2003) Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45, 14-44
112. Elbaz, A., Levecque, C., Clavel, J. et al. (2003) S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov. Disord. 18, 130-137
113. Levecque, C., Destee, A., Mouroux, V. et al. (2001) No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J. Neural Transm. 108, 979-984
114. Mellick, G. D. and Silburn, P. A. (2000) The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci. Lett. 293, 127-130
115. Shi, Q. and Tao, E. (2003) An Ile93Met substitution in the UCH-L1 gene is not a disease-causing mutation for idiopathic Parkinson's disease. Chin. Med. J. 116, 312-313
116. Wang, J., Zhao, C. Y., Si, Y. M., Liu, Z. L., Chen, B. and Yu, L. (2002) ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov. Disord. 17, 767-771
117. Nishikawa, K., Li, H., Kawamura, R. et al. (2003) Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304, 176-183
118. Savettieri, G., De Marco, E. V., Civitelli, D. et al. (2001) Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology 57, 560-561
119. Zhang, J., Hattori, N., Leroy, E. et al. (2000) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat. Disord. 6, 195-197
120. Wintermeyer, P., Kruger, R., Kuhn, W. et al. (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 11, 2079-2082
121. Satoh, J. and Kuroda, Y. (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 189, 113-117
122. Wilkinson, K. D. and Hochstrasser, M. (1998) The deubiquitinating enzyme. In Ubiquitin and the Biology of the Cell (Peters, J. M., Harris, J. R. and Finley, D., eds.), pp. 99-125, Plenum, New York
123. Maraganore, D. M., Farrer, M. J., Hardy, J. A., Lincoln, S. J., McDonnell, S. K. and Rocca, W. A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53, 1858-1860
124. Maraganore, D. M., Lesnick, T. G., Elbaz, A. et al. (2004) UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 55, 512-521
125. Momose, Y., Murata, M., Kobayashi, K. et al. (2002) Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 51, 133-136
126. Liu, Y., Lashuel, H. A., Choi, S. et al. (2003) Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837-846